References
- PetersSAdjeiAAGridelliCReckMKerrKFelipEESMO Guidelines Working GroupMetastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201223Suppl 7vii56vii6422997455
- SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
- SchillerJHHarringtonDBelaniCPEastern Cooperative Oncology GroupComparison of four chemotherapy regimens for advanced non-small-cell lung cancerN Engl J Med20023462929811784875
- FossellaFPereiraJRvon PawelJRandomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study groupJ Clin Oncol200321163016302412837811
- FukuokaMWuYLThongprasertSBiomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)J Clin Oncol201129212866287421670455
- WonYWHanJYLeeGKComparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutationsJ Clin Pathol2011641194795221725039
- SequistLVMartinsRGSpigelDFirst-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutationsJ Clin Oncol200826152442244918458038
- EdelineJBoucherERollandYComparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinomaCancer2012118114715621713764
- MetzgerBChambeauLBegonDYThe human epidermal growth factor receptor (EGFR) gene in European patients with advanced colorectal cancer harbors infrequent mutations in its tyrosine kinase domainBMC Med Genet20111214422026926
- WuJYYuCJChangYCYangCHShihJYYangPCEffectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancerClin Cancer Res201117113812382121531810
- KobayashiSCanepaHMBaileyASCompound EGFR mutations and response to EGFR tyrosine kinase inhibitorsJ Thorac Oncol201381455123242437
- LiuYWuBQZhongHHHuiPFangWGScreening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencingInt J Clin Exp Pathol2013691880188924040454
- MitsudomiTKosakaTEndohHMutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrenceJ Clin Oncol200523112513252015738541
- MokTSWuYLThongprasertSGefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaN Engl J Med20093611094795719692680
- RosellRMoranTQueraltCSpanish Lung Cancer GroupScreening for epidermal growth factor receptor mutations in lung cancerN Engl J Med20093611095896719692684
- ShigematsuHLinLTakahashiTClinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancersJ Natl Cancer Inst200597533934615741570
- ShihJYGowCHYuCJEpidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancerInt J Cancer2006118496396916152581
- GaughanEMCostaDBGenotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalitiesTher Adv Med Oncol20113311312521904575
- RosellRCarcerenyEGervaisRSpanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia ToracicaErlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialLancet Oncol201213323924622285168
- ArcilaMEOxnardGRNafaKRebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assayClin Cancer Res20111751169118021248300
- ChmieleckiJFooJOxnardGROptimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modelingSci Transl Med201139090ra59
- PaoWMillerVAPolitiKAAcquired resistance of lung adeno-carcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domainPLoS Med200523e7315737014
- YuHArcilaMHellmannMKrisMLadanyiMRielyGPoor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testingAnn Oncol201425242342824478319
- KimHRChoBCShimHSPrediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinomaLung Cancer201483337438224468202
- LynchTJBellDWSordellaRActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med2004350212129213915118073
- PaezJGJännePALeeJCEGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyScience200430456761497150015118125
- BoespflugACouraudSBringuierPPPrimary lung adenocar-cinoma occurring in a PTEN related syndrome (Cowden’s disease): routine EGFR sequencing also highlights two rare somatic mutations S768I and V769LLung Cancer201379331832023261230
- MasagoKFujitaSIrisaKGood clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I)Jpn J Clin Oncol201040111105110920522446
- GanesanPAliSMWangKEpidermal growth factor receptor P753S mutation in cutaneous squamous cell carcinoma responsive to cetuximab-based therapyJ Clin Oncol Epub2014616
- HamaTYuzaYSaitoYPrognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinomaOncologist200914990090819726454